Pacific Edge Confirms Novitas to Review Urine Biomarkers for Hematuria; Shares Up 4%

MT Newswires Live

Feb 09

Pacific Edge (NZE:PEB, ASX:PEB) said Medicare Administrative Contractor, Novitas, will hold a Contractor Advisory Committee (CAC) meeting on Feb. 19 to evaluate clinical evidence supporting the use of its urine biomarkers for patients with hematuria, according to a Monday filing with the Australian and New Zealand bourses.

The committee's opinions are likely to influence Novitas' draft local coverage determination regarding Medicare reimbursement for Cxbladder, per the filing.

The company expects to enter a trading halt ahead of the CAC meeting that would remain in place until it provides investors with an update on the discussions, the filing added.

The company's Kiwi shares rose nearly 5% in recent Monday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610503981"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610503981\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610503981?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 06:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610503981","market":"nz","top_or_hot":-1,"title":"Pacific Edge Confirms Novitas to Review Urine Biomarkers for Hematuria; Shares Up 4%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PFGTF\">Pacific Edge</a> (NZE:PEB, ASX:PEB) said Medicare Administrative Contractor, Novitas, will hold a Contractor Advisory Committee (CAC) meeting on Feb. 19 to evaluate clinical evidence supporting the use of its urine biomarkers for patients with hematuria, according to a Monday filing with the Australian and New Zealand bourses.</p><p>The committee's opinions are likely to influence Novitas' draft local coverage determination regarding Medicare reimbursement for Cxbladder, per the filing.</p><p>The company expects to enter a trading halt ahead of the CAC meeting that would remain in place until it provides investors with an update on the discussions, the filing added.</p><p>The company's Kiwi shares rose nearly 5% in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacific Edge Confirms Novitas to Review Urine Biomarkers for Hematuria; Shares Up 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacific Edge Confirms Novitas to Review Urine Biomarkers for Hematuria; Shares Up 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-09 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PFGTF\">Pacific Edge</a> (NZE:PEB, ASX:PEB) said Medicare Administrative Contractor, Novitas, will hold a Contractor Advisory Committee (CAC) meeting on Feb. 19 to evaluate clinical evidence supporting the use of its urine biomarkers for patients with hematuria, according to a Monday filing with the Australian and New Zealand bourses.</p><p>The committee's opinions are likely to influence Novitas' draft local coverage determination regarding Medicare reimbursement for Cxbladder, per the filing.</p><p>The company expects to enter a trading halt ahead of the CAC meeting that would remain in place until it provides investors with an update on the discussions, the filing added.</p><p>The company's Kiwi shares rose nearly 5% in recent Monday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2610503981","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610503981","pubTimestamp":1770591050,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pacific Edge  said Medicare Administrative Contractor, Novitas, will hold a Contractor Advisory Committee  meeting on Feb. 19 to evaluate clinical evidence supporting the use of its urine biomarkers for patients with hematuria, according to a Monday filing with the Australian and New Zealand bourses.The committee's opinions are likely to influence Novitas' draft local coverage determination regarding Medicare reimbursement for Cxbladder, per the filing.The company expects to enter a trading halt ahead of the CAC meeting that would remain in place until it provides investors with an update on the discussions, the filing added.The company's Kiwi shares rose nearly 5% in recent Monday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK4211":"区域性银行","BK8033":"生物科技","CAC":"卡姆登国家银行","PEB.AU":"PACIFIC EDGE LTD","PEB.NZ":"Pacific Edge Limited Ordinary Shares"},"translate_title":"Pacific Edge确认Novitas将审查血尿的尿液生物标志物；股价上涨4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEB.NZ":1.5,"PEB.AU":1,"CAC":1},"content_text":"Pacific Edge (NZE:PEB, ASX:PEB) said Medicare Administrative Contractor, Novitas, will hold a Contractor Advisory Committee (CAC) meeting on Feb. 19 to evaluate clinical evidence supporting the use of its urine biomarkers for patients with hematuria, according to a Monday filing with the Australian and New Zealand bourses.The committee's opinions are likely to influence Novitas' draft local coverage determination regarding Medicare reimbursement for Cxbladder, per the filing.The company expects to enter a trading halt ahead of the CAC meeting that would remain in place until it provides investors with an update on the discussions, the filing added.The company's Kiwi shares rose nearly 5% in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}